(in thousands, except per share data)


	Fiscal 2015 Quarter Ended
	March 31,		June 30,		September 30,		December 31,
Revenues(1)	$	159,275	$	162,984	$	187,611	$	243,881
Net income (loss)	$	(18,359)	$	9,294	$	(39,582)	$	55,178
Basic net income (loss) per share	$	(0.11)	$	0.05	$	(0.22)	$	0.30
Diluted net income (loss) per share	$	(0.11)	$	0.05	$	(0.22)	$	0.29
Shares used in computation of basic net income (loss) per share		172,070		178,676		181,387		186,269
Shares used in computation of diluted net income (loss) per share		172,070		186,493		181,387		193,367


	Fiscal 2014 Quarter Ended
	March 31,		June 30,		September 30,		December 31,
Revenues(2)	$	89,792	$	99,582	$	198,147	$	123,973
Net income (loss)	$	(33,957)	$	(36,873)	$	59,293	$	(36,944)
Basic net income (loss) per share	$	(0.21)	$	(0.22)	$	0.35	$	(0.22)
Diluted net income (loss) per share	$	(0.21)	$	(0.22)	$	0.33	$	(0.22)
Shares used in computation of basic net income (loss) per share		165,357		167,914		168,592		169,924
Shares used in computation of diluted net income (loss) per share		165,357		167,914		189,046		169,924

(1)

The quarters ended March 31, 2015, June 30, 2015, September 30, 2015 and December 31, 2015 include $115.3 million, $142.4 million, $161.3 million and $182.0 million, respectively of product revenues, net, relating to JAKAFI. The quarters ended March 31, 2015, June 30, 2015, September 30, 2015 and December 31, 2015 include $15.7 million, $17.4 million, $18.1 million and $23.6 million, respectively of product royalty revenues related to the sale of JAKAVI outside the United States. In November 2009 and December 2009, we entered into collaborative research and license agreements with Novartis and Lilly, respectively. The quarters ended March 31, 2015, June 30, 2015, September 30, 2015 and December 31, 2015 include $28.2 million, $3.2 million, $8.2 million and $38.2 million, respectively of contract revenues relating to these agreements.

(2)

The quarters ended March 31, 2014, June 30, 2014, September 30, 2014 and December 31, 2014 include $69.7 million, $84.0 million, $97.8 million and $106.0 million, respectively of product revenues, net, relating to JAKAFI. The quarters ended March 31, 2014, June 30, 2014, September 30, 2014 and December 31, 2014 include $9.8 million, $12.3 million, $12.1 million and $14.7 million, respectively of product royalty revenues related to the sale of JAKAVI outside the United States. In November 2009 and December 2009, we entered into collaborative research and license agreements with Novartis and Lilly, respectively. The quarters ended March 31, 2014, June 30, 2014, September 30, 2014 and December 31, 2014 include $10.2 million, $3.2 million, $88.2 million and $3.2 million, respectively of contract revenues relating to these agreements.